Mito Now Offers a $249 No-Referral Heart Scan — Here's What Your Score Really Means
Mito's new direct-access coronary artery calcium scan gives a hard number on arterial plaque — a key heart disease biomarker with real statin-decision implications.
Summary
Mito, a health testing company, now offers a coronary artery calcium (CAC) scan for $249 without a doctor's referral. The quick CT scan counts calcium deposits in coronary artery walls — a sign of hardened plaque — and produces a single score that predicts 10-year heart attack risk far better than blood tests alone. Scores range from 0 (very low risk) to 400-plus (extensive plaque). The 2026 ACC/AHA dyslipidemia guideline recommends the scan for men 40 and older and women 45 and older at borderline or intermediate risk to guide statin decisions. A score of 0 may justify deferring medication; any score above 100 or in the 75th percentile for age and sex triggers a recommendation to start lipid-lowering therapy. Critically, a zero score does not rule out soft, non-calcified plaque.
Detailed Summary
Coronary artery disease remains the leading cause of death in aging adults, yet most people never get a direct look at their arteries until symptoms appear. Mito's new direct-access coronary artery calcium (CAC) scan aims to change that by making a clinically validated imaging biomarker available without a referral, for a flat fee, across all 50 states.
The CAC scan is a brief, needle-free CT of the heart that measures calcium deposits in coronary artery walls. Calcium signals hardened atherosclerotic plaque — the kind that has already set. Results are expressed as a single Agatston score bucketed into four risk bands: 0 (no calcified plaque, very low 10-year risk), 1–99 (mild), 100–399 (moderate), and 400-plus (extensive). Crucially, your report also includes an age- and sex-adjusted percentile, because the same score carries different weight at 45 versus 70.
The clinical backing is substantial. Data from the Multi-Ethnic Study of Atherosclerosis (MESA) — 6,722 adults without established heart disease — found that people scoring above 300 faced roughly 9.7 times the adjusted coronary event risk of those scoring 0 over a median 3.8-year follow-up. The 2026 ACC/AHA dyslipidemia guideline endorses CAC scanning in borderline-to-intermediate-risk men 40 and older and women 45 and older to guide statin initiation. A score of 0 supports deferring lipid-lowering therapy; a score at or above 100 or the 75th age-sex percentile recommends starting it.
Mito prices the scan at $249 for members ($9/month) or $348.60 without. HSA and FSA cards are accepted; most insurers and Medicare do not cover screening CAC scores. Results typically land in your dashboard within 24 hours.
Key caveats: the scan detects only hardened plaque, not soft non-calcified plaque that can still rupture. A score of 0 is reassuring but not a guarantee, particularly in younger adults and smokers. Eligibility criteria Mito uses (any adult 40–75 with one risk factor) are broader than the guideline's target population, so individual clinical context matters. Anyone with active cardiac symptoms should see a physician first.
Key Findings
- A CAC score above 300 confers roughly 9.7× the coronary event risk compared to a score of 0 in the MESA cohort.
- The 2026 ACC/AHA guideline recommends CAC scanning for men 40+ and women 45+ at borderline or intermediate 10-year cardiovascular risk.
- A score of 0 supports deferring statin therapy; a score of 100+ or at the 75th age-sex percentile recommends starting lipid-lowering treatment.
- The scan detects only hardened plaque — a zero score does not rule out soft, rupture-prone non-calcified plaque.
- 44% of statin-eligible adults in MESA had a CAC score of 0, suggesting many people could safely defer medication based on scan results.
Methodology
This is a news report from Longevity.Technology summarizing a commercial product launch by Mito, citing the 2026 ACC/AHA dyslipidemia guideline and published MESA cohort data. The underlying evidence (MESA, n=6,722) is peer-reviewed and the guideline is authoritative, but the article itself has not undergone independent scientific review. No primary research was conducted by the author.
Study Limitations
The article is promotional in framing as it covers a company's product launch, and does not cite the full 2026 ACC/AHA guideline text directly. The scan's inability to detect soft plaque is a meaningful clinical gap not fully elaborated. Readers should verify current guideline eligibility criteria with their physician before purchasing, as Mito's eligibility criteria are broader than the guideline's intended population.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: